secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001628280-24-039023
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Steve Fawell to board; Malcolm Salter retires after nearly a decade
--------------------------------------------------------------------------------

- Malcolm Salter resigned from board effective August 29, 2024, after ~9 years; no disagreements.
- Stephen Fawell, Ph.D. appointed as Class III director through 2026 annual meeting; granted 65,000 share options.
- Fawell has 35 years drug discovery experience, most recently VP head of oncology small molecule discovery at AstraZeneca.
- Ronald Cooper appointed chair of Nominating and Corporate Governance Committee; Bruce Downey added to Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024039023/0001628280-24-039023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024039023/cccc-20240903.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-039023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer